Pyrrolizine-5-carboxamides: Exploring the impact of various substituents on anti-inflammatory and anticancer activities

Gouda, Ahmed M.; Abdelazeem, Ahmed H.; Abdalla, Ashraf N.; Ahmed, Muhammad

doi:10.2478/acph-2018-0026

Abstract

Towards optimization of the pyrrolizine-5-carboxamide scaffold, a novel series of six derivatives (4a-c and 5a-c) was prepared and evaluated for their anti-inflammatory, analgesic and anticancer activities. The (EZ)-7-cyano-6-((4-hydroxybenzylidene)amino)-N-(p-tolyl)-2,3-dihydro-1H-pyrrolizine-5-carboxamide (4b) and (EZ)-6-((4-chlorobenzylidene)-amino)-7-cyano-N-(p-tolyl)-2,3-dihydro-1H-pyrrolizine-5-carboxamide (5b) bearing the electron donating methyl group showed the highest anti-inflammatory activity while (EZ)-6-((4-chlorobenzylidene)amino)-7-cyano-N-phenyl-2,3-dihydro-1H-pyrrolizine-5-carboxamide (5a) was the most active analgesic agent. Cytotoxicity of the new compounds was evaluated against the MCF-7, A2780 and HT29 cancer cell lines using the MTT assay. Compounds 4b and 5b displayed high anticancer activity with IC₅₀ in the range of 0.30–0.92 μmol L⁻¹ against the three cell lines, while compound (EZ)-N-(4-chlorophenyl)-7-cyano-6-((4-hydroxybenzylidene)-amino)-2,3-dihydro-1H-pyrrolizine-5-carboxamide (4c) was the most active against MCF-7 cells (IC₅₀ = 0.08 μmol L⁻¹). Both the anti-inflammatory and anticancer activities of the new compounds were dependent on the type of substituent on the phenyl rings. Substituents with opposite electronic effects on the two phenyl rings are preferable for high cytotoxicity against the MCF-7 and A2780 cells. COX inhibition was suggested as the molecular mechanism of the anti-inflammatory activity of the new compounds while no clear relationship could be observed between COX inhibition and anticancer activity. Compound 5b, the most active against the three cell lines, induced dose-dependent early apoptosis with 0.1–0.2 % necrosis in MCF-7 cells. New compounds showed promising drug-likeness scores while the docking study revealed high binding affinity to COX-2. Taken together, this study highlighted the significant impact of the substituents on the anti-inflammatory and anticancer activity of pyrrolizine-5-carboxamides, which could help in further optimization to discover good leads for the treatment of cancer and inflammation.

References

1. E. R. Rayburn, S. J. Ezell and R. Zhang, Anti-inflammatory agents for cancer therapy, Mol. Cell. Pharmacol.1 (2009) 29–43; https://doi.org/10.4255/mcpharmacol.09.0510.4255/mcpharmacol.09.05284309720333321
Search in Google Scholar Back to article
2. M. J. Thun, S. J. Henley and C. Patrono, Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues, J. Natl. Cancer Inst.94 (2002) 252–266; https://doi.org/10.1093/jnci/94.4.25210.1093/jnci/94.4.25211854387
Search in Google Scholar Back to article
3. S. R. Pedada, N. S. Yarla, P. J. Tambade, B. L. Dhananjaya, A. Bishayee, K. M. Arunasree, G. H. Philip, G. Dharmapuri, G. Aliev, S. Putta and G. Rangaiah, Synthesis of new secretory phospholipase A2-inhibitory indole containing isoxazole derivatives as anti-inflammatory and anticancer agents, Eur. J. Med. Chem.112 (2016) 289–297; https://doi.org/10.1016/j.ejmech.2016.02.02510.1016/j.ejmech.2016.02.02526907155
Search in Google Scholar Back to article
4. C. Sobolewski, C. Cerella, M. Dicato, L. Ghibelli and M. Diederich, The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies, Int. J. Cell Biol.2010 (2010) 1–21; https://doi.org/10.1155/2010/21515810.1155/2010/215158284124620339581
Search in Google Scholar Back to article
5. C. S. Williams, M. Mann and R. N. DuBois, The role of cyclooxygenases in inflammation, cancer, and development, Oncogene18 (1999) 7908–7916; https://doi.org/10.1038/sj.onc.120328610.1038/sj.onc.120328610630643
Search in Google Scholar Back to article
6. C. Ruegg, J. Zaric and R. Stupp, Non-steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and reality, Ann. Med.35 (2003) 476–487; https://doi.org/10.1080/0785389031001705310.1080/0785389031001705314649330
Search in Google Scholar Back to article
7. A. T. Koki and J. L. Masferrer, Celecoxib: a specific COX-2 inhibitor with anticancer properties, Cancer Control9 (2002) 28–35; https://doi.org/10.1177/107327480200902S0410.1177/107327480200902S0411965228
Search in Google Scholar Back to article
8. A. M. Gouda and A. H. Abdelazeem, An integrated overview on pyrrolizines as potential anti-inflammatory, analgesic and antipyretic agents, Eur. J. Med. Chem.114 (2016) 257–292; https://doi.org/10.1016/j.ejmech.2016.01.05510.1016/j.ejmech.2016.01.05526994693
Search in Google Scholar Back to article
9. A. M. Gouda, A. H. Abdelazeem, H. A. Omar, A. N. Abdalla, M. A. S. Abourehab and H. I. Ali, Pyrrolizines: design, synthesis, anticancer evaluation and investigation of the potential mechanism of action, Bioorg. Med. Chem. 25 (2017) 5637–5651; https://doi.org/10.1016/j.bmc.2017.08.039 (in press)10.1016/j.bmc.2017.08.03928916158
Search in Google Scholar Back to article
10. A. M. Gouda, H. I. Ali, W. H. Almalki, M. A. Azim, M. A. S. Abourehab and A. H. Abdelazeem, Design, synthesis, and biological evaluation of some novel pyrrolizine derivatives as COX inhibitors with anti-inflammatory/analgesic activities and low ulcerogenic liability, Molecules21 (2016) 1–21; https://doi.org/10.3390/molecules2102020110.3390/molecules21020201627396326867188
Search in Google Scholar Back to article
11. J.-P. Raynauld, J. Martel-Pelletier, P. Bias, S. Laufer, B. Haraoui, D. Choquette, A. D. Beaulieu, F. Abram, M. Dorais, E. Vignon and J.-P. Pelletier, Protective effects of licofelone, a 5-lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI, Ann. Rheum. Dis.68 (2009) 938–947; https://doi.org/10.1136/ard.2008.08873210.1136/ard.2008.088732
Search in Google Scholar Back to article
12. W. Liu, J. Zhou, K. Bensdorf, H. Zhang, H. Liu, Y. Wang, H. Qian, Y. Zhang, A. Wellner, G. Rubner, W. Huang, C. Guo and R. Gust, Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives, Eur. J. Med. Chem.46 (2011) 907–913; https://doi.org/10.1016/j.ejmech.2011.01.00210.1016/j.ejmech.2011.01.002
Search in Google Scholar Back to article
13. S. Tavolari, M. Bonafe, M. Marini, C. Ferreri, G. Bartolini, E. Brighenti, S. Manara, V. Tomasi, S. Laufer and T. Guarnieri, Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade, Carcinogenesis29 (2008) 371–380; https://doi.org/10.1093/carcin/bgm26510.1093/carcin/bgm265
Search in Google Scholar Back to article
14. S. Tavolari, A. Munarini, G. Storci, S. Laufer, P. Chieco and T. Guarnieri, The decrease of cell membrane fluidity by the non-steroidal anti-inflammatory drug Licofelone inhibits epidermal growth factor receptor signalling and triggers apoptosis in HCA-7 colon cancer cells, Cancer Lett.321 (2012) 187–194; https://doi.org/10.1016/j.canlet.2012.02.00310.1016/j.canlet.2012.02.003
Search in Google Scholar Back to article
15. V. Lisowski, C. Enguehard, J. Lancelot, D. Caignard, S. Lambel, S. Leonce, A. Pierre, G. Atassi, P. Renard and S. Rault, Design, synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents, Bioorg. Med. Chem. Lett.11 (2001) 2205–2208; https://doi.org/10.1016/S0960-894X(01)00403-610.1016/S0960-894X(01)00403-6
Search in Google Scholar Back to article
16. V. Lisowski, S. Leonce, L. Kraus-Berthier, J. Sopkova-de Oliveira Santos, A. Pierre, G. Atassi, D.-H. Caignard, P. Renard and S. Rault, Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents, J. Med. Chem.47 (2004) 1448–1464; https://doi.org/10.1021/jm030961z10.1021/jm030961z14998333
Search in Google Scholar Back to article
17. C. Rochais, T. Cresteil, V. Perri, M. Jouanne, A. Lesnard, S. Rault and P. Dallemagne, MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity, Cancer Lett.331 (2013) 92–98; https://doi.org/10.1016/j.canlet.2012.12.01710.1016/j.canlet.2012.12.01723268332
Search in Google Scholar Back to article
18. A. M. Gouda, A. H. Abdelazeem, E.-S. A. Arafa and K. R. A. Abdellatif, Design, synthesis and pharmacological evaluation of novel pyrrolizine derivatives as potential anticancer agents, Bioorg. Chem.53 (2014) 1–7; https://doi.org/10.1016/j.bioorg.2014.01.00110.1016/j.bioorg.2014.01.00124462996
Search in Google Scholar Back to article
19. A. Etienne and Y. Correia, Derivatives of 2-pyrrolidone, Bull. Soc. Chem.10 (1969) 3704–3712.
Search in Google Scholar Back to article
20. W. A. Jacobs and M. Heidelberger, The ferrous sulfate and ammonia method for the reduction of nitro to amino compounds, J. Am. Chem. Soc.39 (1917) 1435–1439; https://doi.org/10.1021/ja02252a01710.1021/ja02252a017
Search in Google Scholar Back to article
21. M. Y. Ebeid, S. M. El-Moghazy, M. M. Hanna, F. A. Romeih and F. F. Barsoum, Synthesis and anti-HIV activity of some 6,7-dihydro-5H-pyrrolizine-3-carboxamide, 5,6,7,8-tetrahydroindolizine-3-carboxamide, 1-thioxo-1,2,3,5,6,7,8,9,10,11-decahydro-pyrimido-[1,6-a]azonine-4-carbonitrile and 6-thioxo-1,2,5,6,8,9,10,11,12,13,14,14a-dodecahydro-pyrimido[4ʹ,5ʹ:4,5]pyrimido-[1,6-a]azonine-1-one derivatives, Bull. Fac. Pharm. Cairo Univ.35 (1997) 171–183.
Search in Google Scholar Back to article
22. C. A. Winter, E. A. Risley and G. W. Nuss, Carrageenan induced edema in hind paw of the rats as an assay for anti-inflammatory drugs, Proc. Soc. Exp. Biol. Med.111 (1962) 544–547; https://doi.org/10.3181/00379727-111-2784910.3181/00379727-111-2784914001233
Search in Google Scholar Back to article
23. A. Mollica, R. Costante, A. Stefanucci, F. Pinnen, G. Lucente, S. Fidanza and S. Pieretti, Novel cyclic biphalin analogue with improved antinociceptive properties, J. Pept. Sci.19 (2013) 233–239; https://pubs.acs.org/doi/10.1021/ml500241n10.1002/psc.2465
Search in Google Scholar Back to article
24. N. Handler, W. Jaeger, H. Puschacher, K. Leisser and T. Erker, Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors, Chem. Pharm. Bull. (Tokyo) 55 (2007) 64–71; https://doi.org/10.1248/cpb.55.6410.1248/cpb.55.64
Search in Google Scholar Back to article
25. E.-S. A. Arafa, A. H. Abdelazeem, H. H. Arab and H. A. Omar, OSU-CG5, a novel energy restriction mimetic agent, targets human colorectal cancer cells in vitro, Acta Pharmacol. Sin.35 (2014) 394–400; https://doi.org/10.1038/aps.2013.18310.1038/aps.2013.183
Search in Google Scholar Back to article
26. I. Vermes, C. Haanen, H. Steffens-Nakken and C. Reutellingsperger, A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V, J. Immunol. Methods184 (1995) 39–51; https://doi.org/10.1016/0022-1759(95)00072-I10.1016/0022-1759(95)00072-I
Search in Google Scholar Back to article
27. C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv.Rev.23 (1997) 3–25; https://doi.org/10.1016/S0169-409X(96)00423-110.1016/S0169-409X(96)00423-1
Search in Google Scholar Back to article
28. A. Daina, O. Michielin and V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep.7 (2017) Article ID 42717; https://doi.org/10.1038/srep4271710.1038/srep42717533560028256516
Search in Google Scholar Back to article
29. B. S. Selinsky, K. Gupta, C. T. Sharkey and P. J. Loll, Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations, Biochemistry40 (2001) 5172–5180; https://doi.org/10.1021/bi010045s10.1021/bi010045s11318639
Search in Google Scholar Back to article
30. R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. McDonald, R. A. Stegeman, J. Y. Pak, D. Gildehaus, J. M. Miyashiro, T. D. Penning, K. Seibert, P. C. Isakson and W. C. Stallings, Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature384 (1996) 644–648; https://doi.org/10.1038/384644a010.1038/384644a08967954
Search in Google Scholar Back to article

Pyrrolizine-5-carboxamides: Exploring the impact of various substituents on anti-inflammatory and anticancer activities

Abstract

Paradigm

My account